ZALTRAP

This brand name is authorized in Austria, Brazil, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Italy, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, Turkey, United Kingdom, United States

Active ingredients

The drug ZALTRAP contains one active pharmaceutical ingredient (API):

1 Aflibercept UNII 15C2VL427D - AFLIBERCEPT

Aflibercept, also known as VEGF TRAP in the scientific literature, is a recombinant fusion protein consisting of VEGF-binding portions from the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of the human IgG1. Aflibercept blocks the activation of VEGF receptors and the proliferation of endothelial cells, thereby inhibiting the growth of new vessels that supply tumours with oxygen and nutrients. Read about Aflibercept

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ZALTRAP Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01XX44		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX44

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 502817040072707, 502817040072807, 576720050068217, 576720050068317
Country: EE	Ravimiamet	Identifier(s): 1607251, 1607262, 1607273
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 112814001, 112814003
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 125496, 152441
Country: FR	Base de données publique des médicaments	Identifier(s): 60089217
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 222195, 222199
Country: HK	Department of Health Drug Office	Identifier(s): 62551
Country: IT	Agenzia del Farmaco	Identifier(s): 042689012, 042689024, 042689036
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291436A1023, 4291436A2020
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1069238, 1069239, 1069240
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 108383, 108391
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100037810
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W69312001, W69312002, W69312003
Country: SG	Health Sciences Authority	Identifier(s): 14592P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699809980020, 8699809980037, 8699809980044
Country: US	FDA, National Drug Code	Identifier(s): 0024-5840, 0024-5841